Project Grant R01DA060631

This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is for a $1,837,542 project titled "Targeting Treatment-Resistant OUD with Ketamine-Assisted Mindfulness-Oriented Recovery Enhancement." The project aims to investigate the safety, preliminary efficacy, and psycho-physiological mechanisms of combining the psychotherapy Mindfulness-Oriented Recovery Enhancement (MORE) with ketamine...

This Project Grant award of $2,415,940.00, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to develop digital biomarkers and phenotypes for tracking craving patterns in individuals with opioid use disorder (OUD) during medication-based treatment (MOUD). The award will fund a prospective, observational trial of 300 participants initiating MOUD with buprenorphine, methadone or naltrexone. Continuous wearable...

This Project Grant award of $1,476,750.00, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a pilot randomized controlled trial to evaluate the use of the medication semaglutide as an adjunct to buprenorphine for the treatment of opioid use disorder (OUD). The study aims to assess semaglutide's impact on reducing cue-induced craving and its safety and tolerability over a 12-week period in individuals with OUD who...

This federal Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $4,710,576.00 to Mebias Discovery Inc. to develop a new chemical entity, MEB-1170, as a maintenance medication for the treatment of opioid use disorder (OUD). The project aims to complete preclinical studies in rodents and non-human primates to evaluate the efficacy of MEB-1170 in reducing fentanyl self-administration and its safety...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $465,669 to Virginia Commonwealth University (VCU) to conduct a mechanistic study on the role of the orexin system and insomnia within a buprenorphine opioid use disorder (OUD) treatment sample. The study aims to identify differences in drug cue-elicited brain connectivity between OUD patients with and without clinically significant...

This $1,264,863 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund research to evaluate the efficacy and neural mechanisms of combining the medication guanfacine (GXR) and the behavioral intervention Mindfulness Oriented Recovery Enhancement (MORE) as an adjunct to buprenorphine maintenance for individuals with opioid use disorder (OUD). The research will be conducted by Rutgers, The State University...

This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $541,080 to The Trustees of Columbia University in the City of New York to conduct a randomized controlled trial examining the use of extended-release injectable buprenorphine versus sublingual buprenorphine/naloxone in treating opioid use disorder (OUD) among individuals who use high-potency synthetic opioids. The key objectives are to compare abstinence and...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,360,092 to The Medical University of South Carolina to conduct a study titled "Real-World Assessment of Social Functioning During OUD Treatment: Integrating Reports from Patients and Their Concerned Significant Others." The study aims to examine how affiliative social engagement behaviors, social reward, and social connection...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,285,443 to Virginia Commonwealth University (VCU) to conduct a mechanistic study investigating the role of the orexin system in treating opioid use disorder (OUD) and comorbid insomnia. The key products and services to be delivered under this 5-year award include: 1) Examining the effects of the FDA-approved dual orexin receptor antagonist...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $196,236 to The Washington University to conduct research focused on disparities in the prescription and effectiveness of medications to treat opioid use disorder (OUD) during pregnancy. The key objectives of the 5-year project are to: 1) evaluate how race and racial segregation are associated with the use of buprenorphine and methadone as well...